［1］ Parkin D M,Bray F,Chapter .The burden of HPV-related cancers［J］. Vaccine, 2006, 24(Suppl 3),S11-S25.
[2] Shi J F, Belinson J L, Zhao F H,et al.Human papillomavirus testing for cervical cancer screening: results from a 6-year prospective study in rural china［J］. Am J Epidemiology,2009,170(6):708-716.
[3] 杨怡卓，李亚里.人乳头瘤病毒致宫颈癌发生机制研究进展［J］.国外医学妇产科分册，2007,34(4):226-229.
[4] 武明辉,张为远.2007-2008年北京地区25-54岁已婚妇女高危型人乳头瘤病毒感染的流行病学调查［J］.中华妇产科杂志,2009,44（12）:892-897.
[5] 钱德英.子宫颈上皮内瘤变治疗过度与不足得失分析［J］.中国实用妇科和产科杂志，2011,27(7):515-519.
[6] 魏丽惠.何为宫颈癌筛查的适宜方法［J］.中国妇产科临床杂志,2010,11(2):83-84.
[7] 彭小萍，刘继红,李玉洁.宫颈细胞学诊断未能除外高度上皮内瘤样病变的不典型鳞状细胞的临床意义及处理［J］.中国实用妇科与产科杂志，2006，22（10）：765-767.
[8] Bulk S, Berkhof J, Bulkmans N W, et al.Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands［J］. Br J Cancer, 2006, 94(1): 171-175.
[9] 张艾芃,李亚里.人乳头瘤病毒与子宫颈癌临床关系研究进展［J］.国际妇产科学杂志,2010,37(5):311-313.
[10] [JP2]De Sanjosé S, Diaz M, Castellsagué X, et al.Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis［J］. Lancet Infect Dis,2007,7(7):453-459.[JP][JP3]
[11] Koliopoulos G, Arbyn M, Martin-Hirsch P,et al.Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies［J］.Gynecol Oncol,2007,104(1): 232-246.[JP][JP3]
[12] Selleret L, Mathevet P.Precancerous cervical lesions during pregnancy: diagnostic and treatment［J］. J Gynecol Obstet Biol Reprod (Paris), 2008,37:S131-138.[JP]
[13] Yamazaki T, Inaba F, Takeda N,et al.A study of abnormal cervical cytology in pregnant women［J］. Arch Gynecol Obstet,2006,273(5):274-277.
[14] 邓洪梅，梁旭东，魏丽惠.妊娠合并宫颈癌前病变［J］.中国妇产科临床杂志， 2010,11(2):156-157.
[15] 贺昕红,蔺 莉.绝经后妇女宫颈癌特点临床分析［J］.首都医科大学学报,2009,30(4):563-564.
[16] Arbyn M, Sasieni P, Meijer C J,et al. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses［J］. Vaccine,2006,31:S3/78-89.
[17] Heymans J, Benoy I H, Poppe W,et al.Type-specific HPV geno-typing improves detection of recurrent high-grade cervical neoplasia after conisation［J］. Int J Cancer,2011,129(4):903-909.
[18] Kang W D, Oh M J, Kim S M, et al.Significance of human papillomavirus genotyping with high-grade cervical intraepithelial neoplasia treated by a loop electrosurgical excision procedure［J］. Am J Obstet Gynecol,2010,203(1):72-76.
[19] 王 奔,熊正爱.HPV预防性疫苗的现状及研究进展［J］.广东医学, 2011,32(4): 530-532.
[20] Li C, Wu M, Wang J,et al.A population-based study on the risks of cervical lesion and human papillomavirus infection among women in Beijing, People's Republic of China［J］. Cancer Epidemiol Biomarkers Prev, 2010,19(10):2655-2664.［21］ [JP3]Agorastos T, Chatzigeorgiou K, Brotherton J M, et al.Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far［J］. Vaccine,2009,27(52):7270-7281.[JP]［22］ 宋云焕,李 莉.四价疫苗预防宫颈癌HPV感染相关疾病Meta分析［J］.国际妇产科学杂志,2009,36(6)：479-481.［23］ Schellenbacher C, Roden R, Kirnbauer R.Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines［J］. J Virol,2009, 83(19): 10085-10095.